Bhambri R - Search Results

1

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.

Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J. Rozenbaum MH, et al. Among authors: bhambri r. Am J Cardiovasc Drugs. 2022 Jul;22(4):445-450. doi: 10.1007/s40256-022-00526-9. Epub 2022 Mar 30. Am J Cardiovasc Drugs. 2022. PMID: 35353352 Free PMC article. Clinical Trial.

2

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review.

Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J. Rozenbaum MH, et al. Among authors: bhambri r. Cardiol Ther. 2021 Jun;10(1):141-159. doi: 10.1007/s40119-021-00219-5. Epub 2021 Apr 20. Cardiol Ther. 2021. PMID: 33877591 Free PMC article. Review.

3

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.

Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A. Rozenbaum MH, et al. Among authors: bhambri r. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):529-538. doi: 10.1093/ehjqcco/qcab031. Eur Heart J Qual Care Clin Outcomes. 2022. PMID: 33895806 Free PMC article. Clinical Trial.

4

Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy.

Rozenbaum MH, Large S, Bhambri R, Stewart M, Young R, Doornewaard AV, Dasgupta N, Masri A, Nativi-Nicolau J. Rozenbaum MH, et al. Among authors: bhambri r. J Comp Eff Res. 2021 Aug;10(11):927-938. doi: 10.2217/cer-2021-0071. Epub 2021 Jun 18. J Comp Eff Res. 2021. PMID: 34142865 Free article.

5

Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.

Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Bredl Z, Benjumea D, Kemner J, Parasuraman B. Roy A, et al. Among authors: bhambri r. J Manag Care Spec Pharm. 2022 Jul;28(7):766-777. doi: 10.18553/jmcp.2022.28.7.766. J Manag Care Spec Pharm. 2022. PMID: 35737856 Free PMC article.

6

Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.

Bhambri R, Colavecchia AC, Bruno M, Chen Y, Alvir J, Roy A, Kemner J, Crowley A, Benjumea D, Gilstrap L. Bhambri R, et al. Am J Cardiovasc Drugs. 2023 Mar;23(2):197-206. doi: 10.1007/s40256-022-00563-4. Epub 2023 Feb 13. Am J Cardiovasc Drugs. 2023. PMID: 36780092 Free PMC article.

7

Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population.

Bourque JM, Schepart A, Bhambri R, Castaño A, O'Brien A, Chen Y, Prasad S, Roy A, Grodin JL. Bourque JM, et al. Among authors: bhambri r. Am J Cardiol. 2022 Mar 15;167:98-103. doi: 10.1016/j.amjcard.2021.11.048. Epub 2022 Jan 10. Am J Cardiol. 2022. PMID: 35022130 Free article.

8

Incremental Blood Pressure-Lowering Effect of Titrating Amlodipine for the Treatment of Hypertension in Patients Including Those Aged ≥55 Years.

Jeffers BW, Bhambri R, Robbins J. Jeffers BW, et al. Among authors: bhambri r. Am J Ther. 2015 Jul-Aug;22(4):278-87. doi: 10.1097/MJT.0000000000000142. Am J Ther. 2015. PMID: 25370923 Free PMC article. Clinical Trial.

9

Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.

Jeffers BW, Bhambri R, Robbins J. Jeffers BW, et al. Among authors: bhambri r. Vasc Health Risk Manag. 2014 Nov 14;10:651-9. doi: 10.2147/VHRM.S64511. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 25484592 Free PMC article.

10

A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.

Jeffers BW, Robbins J, Bhambri R, Wajsbrot D. Jeffers BW, et al. Among authors: bhambri r. Am J Ther. 2015 Sep-Oct;22(5):322-41. doi: 10.1097/MJT.0000000000000202. Am J Ther. 2015. PMID: 25738570 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page